TITLE

S-1 plus irinotecan: promising alternative treatment in NSCLC

PUB. DATE
September 2008
SOURCE
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p23
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on the use of S-1 and irinotecan in treating non-small cell lung cancer (NSCLC). It references a study which appeared in the 2008 issue of "Clinical Cancer Research." The researchers conducted a phase-2 trial to determine the safety and efficacy of S-1 and irinotecan. Results showed an overall disease control rate of 71.4%. The researchers also found stable disease in 42.9% of patients and progressive disease in 21.4%.
ACCESSION #
34154549

 

Related Articles

  • Lung cancer symptoms and pulse oximetry in the prognostic assessment of patients with lung cancer. Martins, Sandro J.; Ho, Nelson; Cavamura, Sueli O.; Harada, Cecilia M.; Yamamoto, Crystina A.; Takagaki, Teresa Y. // BMC Cancer;2005, Vol. 5, p72 

    Background: Medical oncologists continue to use performance status as a proxy for quality of life (QOL) measures, as completion of QOL instruments is perceived as time consuming, may measure aspects of QOL not affected by cancer therapy, and interpretation may be unclear. The pulse oximeter is...

  • Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Collen, C.; Christian, N.; Schallier, D.; Meysman, M.; Duchateau, M.; Storme, G.; De Ridder, M. // Annals of Oncology;Oct2014, Vol. 25 Issue 10, p1954 

    This prospective phase II trial was designed to investigate the efficacy of SBRT to all disease sites, primary tumor and metastatic locations, in synchronous oligometastatic NSCLC patients. An acceptable disease control and toxicity profile was observed.Background Stereotactic body radiotherapy...

  • Discussions About Clinical Trials Among Patients With Newly Diagnosed Lung and Colorectal Cancer. Kehl, Kenneth L.; Arora, Neeraj K.; Schrag, Deborah; Ayanian, John Z.; Clauser, Steven B.; Klabunde, Carrie N.; Kahn, Katherine L.; Fletcher, Robert H.; Keating, Nancy L. // JNCI: Journal of the National Cancer Institute;Oct2014, Vol. 106 Issue 10, p1 

    Background Clinical trials are essential to establish the effectiveness of new cancer therapies, but less than 5% of adults with cancer enroll in trials. In addition to ineligibility or lack of available trials, barriers to enrollment may include limited patient awareness about the option of...

  • New data suggests new lung cancer drug, Tarceva, extends patient survival.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p9 

    Discusses the phase III study of the efficacy of Tarceva, an investigational lung cancer drug, in improving overall survival of cancer patients. Response rate of cancer patients to the drug; Advancement in treating patients with relapsed non-small cell lung cancer; Diagnosis of lung cancer.

  • Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. Motoshima, Kohei; Nakamura, Yoichi; Sano, Kazumi; Ikegami, Yoji; Ikeda, Takaya; Mizoguchi, Kosuke; Takemoto, Shinnosuke; Fukuda, Minoru; Nagashima, Seiji; Iida, Tetsuya; Tsukamoto, Kazuhiro; Kohno, Shigeru // Cancer Chemotherapy & Pharmacology;Dec2013, Vol. 72 Issue 6, p1299 

    Background: We conducted a phase II trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and evaluated the relationship between plasma concentration and efficacy of erlotinib. Methods: Patients who were...

  • Irinotecan in Extensive Disease Small-Cell Lung Cancer--Impact on European Patients. Hermes, Andreas // European Journal of Clinical & Medical Oncology;2010, Vol. 2 Issue 3, p1 

    In extensive disease small-cell lung cancer, treatment outcome has not changed much during the last 30 years with an overall survival between 8 and 10 months. Several classes of new drugs are now available for patients with non-small cell lung cancer, but to date, there is no comparable efficacy...

  • Quantitative immunohistochemistry in lung cancer: clinical perspective. Szutowicz, Ewa; Dziadziuszko, Rafał // Folia Histochemica et Cytobiologica;2010, Vol. 48 Issue 1, p7 

    Quantitative immunohistochemistry remains an important tool in translational lung cancer research with hopes to improve patient outcomes and avoid unnecessary therapies. Present review is aimed to summarize the use of immunohistochemical markers for improved prognostic information and prediction...

  • Opinion: Genetech/Roche: mixed lung cancer date for Avastin.  // PharmaWatch: Cancer;Jun2008, Vol. 7 Issue 6, p12 

    The author reflects on the results of the phase III trial of Avastin for lung cancer treatment. The author cites the mixed findings revealed by Genentech Inc. about the efficacy of the drug. According to the author, the proven efficacy of Avastin with different chemotherapy regimens may increase...

  • How Today’s Developments in the Treatment of Non-Small Cell Lung Cancer Will Change Tomorrow’s Standards of Care. Mark G. Kris // Oncologist;Oct2005, Vol. 10 Issue 9, p23 

    Cisplatin (Platinol®; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com) and carboplatin (Paraplatin®; Bristol-Myers Squibb), together with newer chemotherapies, such as docetaxel (Taxotere®; Aventis Pharmaceuticals Inc., Bridgewater, NJ, http://www.aventispharma-us.com),...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics